Lower-Dose CagriSema Cuts Body Weight by About a Fifth
Graded Moderate — a double-blind trial with random assignment in 309 adults over 68 weeks; it is too small and too short to judge rare side effects or long-term effects.
- Design
- Randomized controlled trial
- Participants
- 309
- Duration
- 16 months
- Funding
- Novo Nordisk
Adults with overweight lost about a fifth of their body weight on CagriSema, even at 1.7 or 1.0 milligrams of each drug.
A weekly injection combining two drugs, cagrilintide and semaglutide, helped adults with overweight lose about a fifth of their body weight. It did so at doses below the 2.4 milligrams of each drug tested in earlier large trials. This study tried 1.7 and 1.0 milligrams of each.
The trial ran at 24 clinics in Canada, France, Germany, the UK and the US. It enrolled 309 adults without diabetes, on average 48 years old, about three quarters of them women. Chance decided who injected the drug and who injected a dummy shot for 68 weeks. Everyone also received advice on diet and activity. Weight fell by an average of 20.7 percent on the 1.7 mg dose, 21.0 percent on the 1.0 mg dose and 2.0 percent on the dummy shot. These figures assume everyone kept injecting as planned.
Nearly everyone reported side effects, including 91 percent of the dummy-shot group. Most were mild or moderate and affected the stomach and gut. No one died. The two doses were not tested head to head. The drug company Novo Nordisk paid for the study.
Conflict of Interest Disclosure: Novo Nordisk funded the trial, two authors are its employees, another works on assignment there, and several received fees from drug companies.
Disclaimer: Research summaries are provided for informational purposes only and do not constitute medical advice. Always consult a qualified healthcare professional before making changes to your health routine.
Topics
